QAdvis and Scandinavian CRO join Aurevia to strengthen clinical research and regulatory expertise

In January 2025, the Aurevia brand was established when Labquality, Artimed, Clinical Consulting, Kasve, and Prisma CRO merged under the same name. Now, Scandinavian CRO (SCRO) and QAdvis, clinical research and quality/regulatory experts in Sweden, will also operate under the name of Aurevia. With SCRO and QAdvis fully integrated into the team, Aurevia offers greater value to its customers in the medtech, biotech and pharmaceutical sectors.

As a result of the merger, Aurevia becomes an even stronger full-service Contract Research Organization (CRO) supporting pharmaceuticals, medical devices, and in vitro diagnostic devices, covering all phases of development. In addition, the company’s Quality Assurance and Regulatory Affairs (QARA) services are now expanding to provide comprehensive support to navigate complex requirements, while External Quality Assessment Services (EQAS) ensure clinical laboratories meet required quality standards.

"Our legacy of innovation and expertise will continue, while our growing capabilities ensure comprehensive, agile service. Built on a strong foundation, we are now a larger, united team across four European countries, serving customers in over 60 countries,” says Juha-Pekka Nuutinen, Aurevia’s CEO.

“We are a team of highly skilled experts with decades of experience working in clinical research, and we take pride in valuing our people and relationships. Together with our QARA colleagues, we can support our clients throughout their product development lifecycle,” says Ulrika Hammarström, Head of CRO at Aurevia and former CEO and Founder of SCRO.

With teams in Sweden, Poland, Germany and Finland, Aurevia now builds on the legacy of SCRO and QAdvis by strengthening partnerships with the Swedish industry, healthcare sector, and academia.

"Our consultants are thought leaders that understand evolving regulations and the tough challenges that our customers face,” says Anna-Karin Alm, Head of QARA at Aurevia and former CEO of QAdvis. She continues: “By joining forces, we are creating a solid platform for future growth, not only for us, but for our clients.”

With this merger, Aurevia strengthens its position as a trusted CRO partner for both medical devices and pharmaceuticals, especially across the Nordics and Europe. Aurevia’s global offering reaches beyond clinical research, as the company’s QARA expertise covers the entire lifecycle of medical devices and in vitro diagnostics from early development to post-marketing activities, and our EQAS offering ensures clinical laboratories meet required quality standards.

To learn more about Aurevia and our expanded offering, visit aurevia.com.

We look forward to continuing our work under our new name — Aurevia — with even more expertise, innovation, and flexible solutions to meet our clients’ business needs and challenges.

For queries, please contact:

Juha-Pekka Nuutinen
CEO | Aurevia
+358 40 828 3210 | juha-pekka.nuutinen@aurevia.com

AUREVIA

As Aurevians, we are the excellence makers: a team of experienced experts in healthcare and health-tech standards and quality. Together, we advance healthcare, pharmaceutical and medical technology development with a future-focused approach, aligned with client needs. Driven by our commitment to care, we contribute quality to the industry and pave the way for safer, more effective patient care worldwide.

We are a full-service, rapid-response Contract Research Organization (CRO) and external quality assessment services (EQAS) provider. Our quality services for the healthcare, pharmaceutical, and medical technology industries cover external quality assessments, quality assurance, regulatory affairs, clinical investigations and trials, audits and certifications, and training. Our expertise and knowledge benefit medical device and in vitro diagnostic manufacturers, pharmaceutical companies, healthcare units, and clinical laboratories.

Currently, we serve over 8000 customers in over 60 countries around the world. Our team comprises nearly 200 skilled professionals in offices in Finland, Sweden, Poland, and Germany. Aurevia is supported by Mérieux Equity Partners.

Aurevia – empowering clients with excellence-driven solutions to achieve the highest standards in patient care.